The discovery and optimisation of pyrido[2,3-d]pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR kinase

被引：76

作者：

Malagu, Karine ^{[2
]}

Duggan, Heather ^{[2
]}

Menear, Keith ^{[2
]}

Hummersone, Marc ^{[2
]}

Gomez, Sylvie ^{[2
]}

Bailey, Christine ^{[2
]}

Edwards, Peter ^{[2
]}

Drzewiecki, Jan ^{[2
]}

Leroux, Frederic ^{[2
]}

Quesada, Mar Jimenez ^{[2
]}

Hermann, Gesine ^{[2
]}

Maine, Stephanie ^{[2
]}

Molyneaux, Carrie-Anne ^{[2
]}

Le Gall, Armelle ^{[2
]}

Pullen, James ^{[2
]}

Hickson, Ian ^{[2
]}

Smith, Lisa ^{[2
]}

Maguire, Sharon ^{[2
]}

Martin, Niall ^{[2
]}

Smith, Graeme ^{[1
,2
]}

Pass, Martin ^{[1
]}

机构：

[1] AstraZeneca, Macclesfield SK10 4TG, Cheshire, England

[2] KuDOS Pharmaceut Ltd, Cambridge 3B4 0WG, England

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2009年 / 19卷 / 20期

关键词：

Antitumour; mTOR; Serine/threonine kinase; SIGNALING FUNCTIONS; MAMMALIAN PROTEIN; RAPAMYCIN; TARGET; WORTMANNIN; LY294002; PATHWAY; S6K1;

D O I：

10.1016/j.bmcl.2009.08.038

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

We describe a novel series of potent inhibitors of the kinase activity of mTOR. The compounds display good selectivity relative to other PI3K-related kinase family members and, in cellular assays, inhibit both mTORC1 and mTORC2 complexes and exhibit good antiproliferative activity. (C) 2009 Elsevier Ltd. All rights reserved.

引用

收藏

页码：5950 / 5953

页数：4

相关论文

共 17 条

[1] Phosphatidylinositol 3-kinase related kinases [J].

Abraham, RT .

CURRENT OPINION IN IMMUNOLOGY, 1996, 8 (03) :412-418

[2]

BAILEY JP, 2006, Patent No. 2006005914

[3] A MAMMALIAN PROTEIN TARGETED BY G1-ARRESTING RAPAMYCIN-RECEPTOR COMPLEX [J].

BROWN, EJ ;

ALBERS, MW ;

SHIN, TB ;

ICHIKAWA, K ;

KEITH, CT ;

LANE, WS ;

SCHREIBER, SL .

NATURE, 1994, 369 (6483) :756-758

[4] Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002 [J].

Brunn, GJ ;

Williams, J ;

Sabers, C ;

Wiederrecht, G ;

Lawrence, JC ;

Abraham, RT .

EMBO JOURNAL, 1996, 15 (19) :5256-5267

[5]

Edinger AL, 2003, CANCER RES, V63, P8451

[6] Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2 [J].

Feldman, Morris E. ;

Apsel, Beth ;

Uotila, Aino ;

Loewith, Robbie ;

Knight, Zachary A. ;

Ruggero, Davide ;

Shokat, Kevan M. .

PLOS BIOLOGY, 2009, 7 (02) :371-383

[7] Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E [J].

Fingar, DC ;

Salama, S ;

Tsou, C ;

Harlow, E ;

Blenis, J .

GENES & DEVELOPMENT, 2002, 16 (12) :1472-1487

[8] mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E [J].

Fingar, DC ;

Richardson, CJ ;

Tee, AR ;

Cheatham, L ;

Tsou, C ;

Blenis, J .

MOLECULAR AND CELLULAR BIOLOGY, 2004, 24 (01) :200-216

[9] Selective benzopyranone and pyrimido[2,1-α]isoquinolin-4-one inhibitors of DNA-dependent protein kinase:: Synthesis, structure-activity studies, and radiosensitization of a human tumor cell line in vitro [J].

Griffin, RJ ;

Fontana, G ;

Golding, BT ;

Guiard, S ;

Hardcastle, IR ;

Leahy, JJJ ;

Martin, N ;

Richardson, C ;

Rigoreau, L ;

Stockley, M ;

Smith, GCM .

JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (02) :569-585

[10] Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM [J].

Hickson, I ;

Yan, Z ;

Richardson, CJ ;

Green, SJ ;

Martin, NMB ;

Orr, AI ;

Reaper, PM ;

Jackson, SP ;

Curtin, NJ ;

Smith, GCM .

CANCER RESEARCH, 2004, 64 (24) :9152-9159